Ritchie, Ellen K.

Publications

Sort by

Co-Author Network

selected publications

Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial. Haematologica. 2023 Academic Article GET IT
Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML. Leukemia & lymphoma. 2023 Academic Article GET IT
Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome. Leukemia & lymphoma. 2022 Academic Article GET IT
Patient-reported outcomes of patients with myelofibrosis or essential thrombocythemia enrolled in the MOST study. Leukemia & lymphoma. 2022 Academic Article GET IT
MPN-186 Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden: Analysis of Data from the MOST Study. Clinical lymphoma, myeloma & leukemia. 2022 Academic Article GET IT
MPN-469 Rusfertide (PTG-300) Treatment Interruption Reverses Hematological Gains and Upon Reinitiation, Restoration of Clinical Benefit Observed in Patients With Polycythemia Vera. Clinical lymphoma, myeloma & leukemia. 2022 Academic Article GET IT
Hematopoietic fitness of JAK2V617F myeloproliferative neoplasms is linked to clinical outcome. Blood advances. 2022 Academic Article GET IT
Times cited: 2
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Academic Article GET IT
Times cited: 28
Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101. Blood advances. 2022 Academic Article GET IT
Times cited: 4
A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia. Investigational new drugs. 2022 Academic Article GET IT
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Academic Article GET IT
Times cited: 31
Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML. Frontiers in oncology. 2021 Academic Article GET IT
Times cited: 103
Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica. 2021 Academic Article GET IT
Times cited: 14
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. The Lancet. Haematology. 2021 Academic Article GET IT
Times cited: 53
Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia. 2021 Academic Article GET IT
Times cited: 38
A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome. Leukemia & lymphoma. 2021 Academic Article GET IT
Times cited: 11
Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study. European journal of cancer (Oxford, England : 1990). 2021 Academic Article GET IT
Times cited: 25
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. JAMA oncology. 2021 Academic Article GET IT
Times cited: 28
Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. Blood advances. 2020 Academic Article GET IT
Times cited: 4
Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy. Leukemia & lymphoma. 2020 Letter GET IT
Times cited: 1
Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. CA: a cancer journal for clinicians. 2020 Academic Article GET IT
Times cited: 12
Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3. Blood. 2020 Letter GET IT
Times cited: 14
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia. 2020 Academic Article GET IT
Times cited: 37
Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. Leukemia & lymphoma. 2020 Letter GET IT
Times cited: 11
Acute Myeloid Leukemia Presenting as Myeloid Sarcoma with a Predisposition to the Gynecologic Tract. 2019 GET IT
Times cited: 15
Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia. Leukemia & lymphoma. 2019 Academic Article GET IT
Times cited: 10
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. Blood. 2019 Academic Article GET IT
Times cited: 97
Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). Journal of geriatric oncology. 2019 Academic Article GET IT
Times cited: 27
Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary Hypertension. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. 2019 Academic Article GET IT
Times cited: 9
Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/BCR-FGFR1-rearranged myeloid/lymphoid neoplasm with RUNX1 mutation - diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib. Leukemia & lymphoma. 2019 Letter GET IT
Times cited: 2
Drug development challenges in polycythemia vera. Blood. 2019 Comment GET IT
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. Leukemia. 2019 Letter GET IT
Times cited: 15
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. The Lancet. Haematology. 2019 Academic Article GET IT
Times cited: 60
Corrigendum to "Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib" [Leukemia Res. 79 (2019) 38-44]. Leukemia research. 2019 Article GET IT
Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. Leukemia research. 2019 Academic Article GET IT
Times cited: 23
Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective. Leukemia & lymphoma. 2019 Academic Article GET IT
Times cited: 3
Differentiating factors in treatment-free remission trials: impact of study design on results and clinical applications. Leukemia & lymphoma. 2018 Review GET IT
Times cited: 1
Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Academic Article GET IT
Times cited: 3
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood advances. 2018 Academic Article GET IT
Times cited: 80
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 571
Somatic mutations precede acute myeloid leukemia years before diagnosis. Nature medicine. 2018 Academic Article GET IT
Times cited: 338
Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leukemia & lymphoma. 2018 Letter GET IT
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica. 2018 Letter GET IT
Times cited: 7
Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia. Haematologica. 2018 Academic Article GET IT
Times cited: 29
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood advances. 2018 Academic Article GET IT
Times cited: 95
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2018 Academic Article GET IT
Times cited: 5
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC cancer. 2018 Academic Article GET IT
Times cited: 14
Will tyrosine kinase inhibitors be part of the treatment armamentarium for CML in the future?. Expert opinion on pharmacotherapy. 2018 Editorial Article GET IT
Times cited: 1
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer. 2017 Academic Article GET IT
Times cited: 49
CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine. Leukemia & lymphoma. 2017 Academic Article GET IT
Times cited: 10
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. The Lancet. Oncology. 2017 Academic Article GET IT
Times cited: 346
The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis. Cancer. 2017 Academic Article GET IT
Times cited: 40
Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations. The Journal of molecular diagnostics : JMD. 2017 Academic Article GET IT
Times cited: 61
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 274
Acute myeloid leukemia in a patient with thrombocytopenia with absent radii: A case report and review of the literature. Hematology/oncology and stem cell therapy. 2017 Review GET IT
Times cited: 9
Role of Cost-Sharing Subsidies on the Initiation of and Adherence to Tyrosine Kinase Inhibitor Therapy by Medicare Beneficiaries With Chronic Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Letter GET IT
Times cited: 3
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. Leukemia. 2016 Academic Article GET IT
Times cited: 33
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clinical lymphoma, myeloma & leukemia. 2016 Academic Article GET IT
Times cited: 12
Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Review GET IT
Times cited: 49
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. The Lancet. Oncology. 2015 Academic Article GET IT
Times cited: 118
Clinical and molecular epidemiology of human rhinovirus infections in patients with hematologic malignancy. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2015 Academic Article GET IT
Times cited: 27
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis. Leukemia & lymphoma. 2015 Academic Article GET IT
Times cited: 26
Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome. Leukemia & lymphoma. 2015 Academic Article GET IT
Times cited: 3
Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 55
The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). Leukemia research. 2014 Academic Article GET IT
Times cited: 57
Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. British journal of haematology. 2013 Academic Article GET IT
Times cited: 61
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2013 Academic Article GET IT
Times cited: 14
Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia. Leukemia & lymphoma. 2013 Academic Article GET IT
Times cited: 126
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome. Clinical interventions in aging. 2012 Review GET IT
Times cited: 14
Blood simple: transfusion at home for patients with MDS. Leukemia research. 2012 Editorial Article GET IT
Times cited: 3
Are low-intensity induction strategies better for older patients with acute myeloid leukemia?. Leukemia research. 2012 Academic Article GET IT
Times cited: 8
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood. 2011 Academic Article GET IT
Times cited: 23
Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood. 2011 Academic Article GET IT
Times cited: 116
Lethal T- and NK-cell lymphomas mimicking granulomatous panniculitidies: a clinicopathologic study of three cases. 2011 GET IT
Times cited: 3
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 257
Autologous hematopoietic stem-cell transplantation in combination with thalidomide as treatment for histiocytic sarcoma: a case report and review of the literature. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Review GET IT
Times cited: 37
Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndrome. Leukemia research. 2010 Academic Article GET IT
Times cited: 8
Levels of care: defining best supportive care in elderly patients with acute myeloid leukemia. Current hematologic malignancy reports. 2010 Review GET IT
Times cited: 8
Management of myelodysplastic syndromes in the geriatric patient. Current hematologic malignancy reports. 2009 Academic Article GET IT
Times cited: 6
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood. 2008 Academic Article GET IT
Times cited: 51
Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia. Cancer. 2008 Academic Article GET IT
Times cited: 45
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia. 2008 Academic Article GET IT
Times cited: 173
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma. 2007 GET IT
Times cited: 21
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2006 Academic Article GET IT
Times cited: 387
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 22
Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy. Current cancer drug targets. 2006 Review GET IT
Times cited: 22
Incidence rates of the major leukemia subtypes among US Hispanics, Blacks, and non-Hispanic Whites. Leukemia & lymphoma. 2006 Academic Article GET IT
Times cited: 53
Incidence rates of acute promyelocytic leukemia among Hispanics, blacks, Asians, and non-Hispanic whites in the United States. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP). 2006 Academic Article GET IT
Times cited: 39
Ikaros increases normal apoptosis in adult erythroid cells. American journal of hematology. 2006 Academic Article GET IT
Times cited: 11
The cost of HIV medication adherence support interventions: results of a cross-site evaluation. AIDS care. 2005 Academic Article GET IT
Times cited: 17

more ...

less ...

Background

education and training

M.D., Columbia University College of Physicians and Surgeons 1997
A.B., Barnard College - Columbia University 1983

Contact

full name

Ellen K. Ritchie

primary email

ritchie@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Ellen K. Ritchie Associate Professor of Clinical Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email

webpage